Trial Profile
A single-blind, placebo-controlled study of subcutaneously administered benralizumab in healthy male volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 17 Aug 2015 New trial record